Abstract: This case study highlights a female military veteran and her intimate partner who participated in an open label clinical trial receiving brief Cognitive-Behavioral Conjoint Therapy (bCBCT) enhanced with two 3,4-methylenedioxymethamphetamine (MDMA) sessions to treat posttraumatic stress disorder (PTSD) and relationship functioning. Both partners participated in therapy and only the veteran diagnosed with PTSD received MDMA. Results suggest significant PTSD symptom reduction for the veteran (pretreatment CAPS-5 severity = 51, immediate posttreatment CAPS-5 = 22, 3-months posttreatment CAPS-5 = 28, and 6-months posttreatment CAPS-5 = 21) and maintenance of high relationship satisfaction (pretreatment CSI-32 = 136, immediate post CSI-32 = 140, 3-months posttreatment CSI-32 = 137, and 6-months posttreatment CSI-32 = 129). This case illustrates a novel and scalable delivery of MDMA-assisted bCBCT using an outpatient model and highlights the importance of including loved ones, such as intimate partners, in MDMA treatment and integration.